Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 27, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Benz Edward J. JR (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.46	2027-04-05	Common Stock (32548)		Direct
Stock Option (Right to Buy)	$1.46	2028-08-17	Common Stock (4068)		Direct
Stock Option (Right to Buy)	$1.55	2030-12-14	Common Stock (16274)		Direct
Stock Option (Right to Buy)	$6.64	2031-06-23	Common Stock (16274)		Direct

Footnotes

F1: This option shall vest and become exercisable in four substantially equal annual installments, with the first installment vested on October 4, 2018.

F2: 25% of this option vested and became exercisable on May 28, 2019, with an additional 25% vesting on January 1, 2020 and the remainder vesting in 36 substantially equal monthly installments thereafter.

F3: This option is fully vested and exercisable as of the date hereof.